The assessment of BRCA1 and BRCA2 coding sequences to identify pathogenic mutations associated with inherited breast/ovarian cancer syndrome has provided a method to identify high-risk individuals, allowing them to seek preventative treatments and strategies. However, the current test is expensive, and cannot differentiate between pathogenic variants and those that may be benign. Focusing only on one of the two BRCA partners, we have developed a biological assay for haploinsufficiency of BRCA1. Using a series of EBV-transformed cell lines, we explored gene expression patterns in cells that were BRCA1 wildtype compared to those that carried (heterozygous) BRCA1 pathogenic mutations. We identified a subset of 43 genes whose combined expressio...
Genome-wide studies of patients carrying pathogenic variants (mutations) in BRCA1 or BRCA2 have repo...
Patients with germline mutations in BRCA1 or BRCA2 genes are predisposed to breast cancer. The BRCA1...
Germline mutations that inactivate BRCA1 are responsible for breast and ovarian cancer susceptibilit...
The assessment of BRCA1 and BRCA2 coding sequences to identify pathogenic mutations associated with ...
Abstract: Mutations in two major genes, BRCA1 and BRCA2, account for up to 30 % of families with her...
BRCA1 acts a tumor suppressor gene and germ-line mutations which disrupt its functions culminate, af...
Family members with a heritable mutation in the BRCA1 or BRCA2 gene have up to an 85% life-long risk...
Background: BRCA1 is a tumour suppressor with pleiotropic actions. Germline mutations in BRCA1 are r...
Germ-line mutations in the BRCA1 gene cause hereditary predisposition to breast and ovarian cancer. ...
BRCA1 and BRCA2 are the genes related with breast and ovarian cancer. They have function in DNA repa...
The identification of variants of unknown clinical significance (VUS) in the BRCA1 gene complicates ...
The functional consequences of missense variants in disease genes are difficult to predict. We asses...
We searched for a founder mutation in a population from one geographic region of Norway with prevale...
Genome-wide studies of patients carrying pathogenic variants (mutations) in BRCA1 or BRCA2 have repo...
M1775R and A1789T are two missense variants located within the BRCT domain of BRCA1 gene, both isola...
Genome-wide studies of patients carrying pathogenic variants (mutations) in BRCA1 or BRCA2 have repo...
Patients with germline mutations in BRCA1 or BRCA2 genes are predisposed to breast cancer. The BRCA1...
Germline mutations that inactivate BRCA1 are responsible for breast and ovarian cancer susceptibilit...
The assessment of BRCA1 and BRCA2 coding sequences to identify pathogenic mutations associated with ...
Abstract: Mutations in two major genes, BRCA1 and BRCA2, account for up to 30 % of families with her...
BRCA1 acts a tumor suppressor gene and germ-line mutations which disrupt its functions culminate, af...
Family members with a heritable mutation in the BRCA1 or BRCA2 gene have up to an 85% life-long risk...
Background: BRCA1 is a tumour suppressor with pleiotropic actions. Germline mutations in BRCA1 are r...
Germ-line mutations in the BRCA1 gene cause hereditary predisposition to breast and ovarian cancer. ...
BRCA1 and BRCA2 are the genes related with breast and ovarian cancer. They have function in DNA repa...
The identification of variants of unknown clinical significance (VUS) in the BRCA1 gene complicates ...
The functional consequences of missense variants in disease genes are difficult to predict. We asses...
We searched for a founder mutation in a population from one geographic region of Norway with prevale...
Genome-wide studies of patients carrying pathogenic variants (mutations) in BRCA1 or BRCA2 have repo...
M1775R and A1789T are two missense variants located within the BRCT domain of BRCA1 gene, both isola...
Genome-wide studies of patients carrying pathogenic variants (mutations) in BRCA1 or BRCA2 have repo...
Patients with germline mutations in BRCA1 or BRCA2 genes are predisposed to breast cancer. The BRCA1...
Germline mutations that inactivate BRCA1 are responsible for breast and ovarian cancer susceptibilit...